An American Journal of Managed Care® Patient Perspective: Treating Idiopathic Pulmonary Fibrosis

The study is the first to evaluate a fixed-duration regimen of venetoclax, the first-generation BCL2 inhibitor, with a second-generation Bruton tyrosine kinase inhibitor, acalabrutinib, in chronic lymphocytic leukemia (CLL).

On this episode of Managed Care Cast, we speak with CVS Health's vice president and chief medical officer for women's health and genomics about advancements and challenges in women's health, focusing on care access, technology, and maternal outcomes.

New insights underscore the value of considering sleep variability when addressing inequities in pediatric sleep health.

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

The inMIND trial was the first to examine dual targeting of CD19 and CD20 in follicular lymphoma.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).